SCHEMBL2697740

SCHEMBL2697740

O=C1c2ccccc2C(=O)N1CC1CCC(c2ccccc2)O1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SLC6A2 P23975 1/20 0.54
SLC6A4 P31645 1/20 0.54
SLC6A3 Q01959 1/20 0.54
ALDH1A1 P00352 2/20 0.46
CTSD P07339 7/20 0.46
KDM4E B2RXH2 1/20 0.43
ACHE P22303 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2745254 0.92 CYP1A2 (0.59) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2689807 0.89 SLC6A2 (0.54) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2690627 0.89 SLC6A2 (0.54) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL13073610 0.87 CYP2A6 (0.61) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2691186 0.86 SLC6A2 (0.56) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2692008 0.86 SLC6A2 (0.56) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2689170 0.84 SLC6A2 (0.60) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL2744965 0.82 CYP2C9 (0.56) CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL2689172 0.80 SLC6A2 (0.61) CYP1A2CYP2C9CYP2C19SLC6A2SLC6A4
SCHEMBL14626313 0.79 CYP2C9 (0.57) CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123253-A1 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-05-16 US disclosed
US-8168635-B2 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-05-01 US disclosed
US-20080261967-A1 Modulators of Central Nervous System Neurotransmitters HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-10-23 US disclosed
EP-1771435-A4 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RES INST (US) 2008-02-13 EP disclosed
EP-1771435-A2 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS Human Biomolecular Research Institute (US) 2007-04-11 EP disclosed
WO-2006025920-A2 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261967-A1 Modulators of Central Nervous System Neurotransmitters GAP43, SLC18A2, CHRNA6 CYP1A2 2907/4885CYP2C9 4487/4885CYP2C19 4423/4885
US-20130123253-A1 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS GAP43, SLC18A2, CHRNA6 CYP1A2 2907/4885CYP2C9 4487/4885CYP2C19 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.